Hematology-Oncology
Latest news
269 articles · 20 / page
Venous Thromboembolism in Newly Diagnosed Lymphoma Patients: Insights from a Real-World Vietnamese Cohort
An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.
Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma
This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advance
Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell ly
Can Eltrombopag Transform Aplastic Anemia Care?
Eltrombopag combined with immunosuppressive therapy shows promising efficacy in severe aplastic anemia, especially in relapsed/refractory pediatric patients, with over half achieving hematologic responses and transfusion independence, suppo
Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial
KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.
Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po
Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
Hetrombopag vs. Thrombopoietin for Platelet Engraftment After Allogeneic Stem Cell Transplantation: New Evidence from a Multicenter Randomized Controlled Trial
Hetrombopag demonstrates comparable efficacy and safety to thrombopoietin for platelet engraftment after allogeneic hematopoietic stem cell transplantation, offering a promising alternative in hematologic care.
Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results
The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.
Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE Trial
Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.
Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities
Subcutaneous blinatumomab demonstrates promising efficacy and manageable safety in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with potential to shift future administration paradigms.
Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials
Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.
Browse by specialty
Open language-specific specialty feeds and department pages.